76 related articles for article (PubMed ID: 21664066)
1. Role of isotope selection in long-term outcomes in patients with intermediate-risk prostate cancer treated with a combination of external beam radiotherapy and low-dose-rate interstitial brachytherapy.
Wernicke AG; Shamis M; Yan W; Trichter S; Sabbas AM; Goltser Y; Christos PJ; Brennan JS; Parashar B; Nori D
Urology; 2012 May; 79(5):1098-104. PubMed ID: 22546388
[TBL] [Abstract][Full Text] [Related]
2. Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation.
Narang AK; Gergis C; Robertson SP; He P; Ram AN; McNutt TR; Griffith E; DeWeese TA; Honig S; Singh H; Song DY; Tran PT; DeWeese TL
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):254-62. PubMed ID: 26853334
[TBL] [Abstract][Full Text] [Related]
3. Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907).
Yorozu A; Namiki M; Saito S; Egawa S; Yaegashi H; Konaka H; Momma T; Fukagai T; Tanaka N; Ohashi T; Takahashi H; Nakagawa Y; Kikuchi T; Mizokami A; Stone NN
Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):390-401. PubMed ID: 37802225
[TBL] [Abstract][Full Text] [Related]
4. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer.
Nguyen PL; Martin NE; Choeurng V; Palmer-Aronsten B; Kolisnik T; Beard CJ; Orio PF; Nezolosky MD; Chen YW; Shin H; Davicioni E; Feng FY
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):186-192. PubMed ID: 28117383
[TBL] [Abstract][Full Text] [Related]
5. LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients.
Boehle A; Zywietz D; Robrahn-Nitschke I; Lusch A; König IR
Urol Oncol; 2023 Nov; 41(11):454.e17-454.e24. PubMed ID: 37714724
[TBL] [Abstract][Full Text] [Related]
6. Improved outcomes after radiotherapy for prostate cancer: Anticoagulation, antiplatelet therapy, and platelet count as key factors in disease progression.
Gutiontov SI; Choe KS; Miller JL; Liauw SL
Cancer Med; 2020 Jul; 9(13):4667-4675. PubMed ID: 32400122
[TBL] [Abstract][Full Text] [Related]
7. Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system.
Herr DJ; Elliott DA; Duchesne G; Stensland KD; Caram MEV; Chapman C; Burns JA; Hollenbeck BK; Sparks JB; Shin C; Zaslavsky A; Tsodikov A; Skolarus TA
Cancer; 2023 Oct; 129(20):3326-3333. PubMed ID: 37389814
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localized Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-Year Experience.
Habashy D; Reddy D; Peters M; Shah TT; van Son M; van Rossum PSN; Tanaka MB; Cullen E; Engle R; McCracken S; Greene D; Hindley RG; Emara A; Nigam R; Orczyk C; Shergill I; Persad R; Virdi J; Moore CM; Arya M; Winkler M; Emberton M; Ahmed HU; Dudderidge T
J Urol; 2023 Jul; 210(1):108-116. PubMed ID: 37014172
[TBL] [Abstract][Full Text] [Related]
9. ACR-ABS-ASTRO Practice Parameter for Transperineal Permanent Brachytherapy of Prostate Cancer.
Bittner NHJ; Cox BW; Davis B; King M; Lawton CAF; Merrick GS; Orio P; Ouhib Z; Rossi P; Showalter T; Small W; Schechter NR
Am J Clin Oncol; 2022 Jun; 45(6):249-257. PubMed ID: 35588224
[TBL] [Abstract][Full Text] [Related]
10. Estimated absolute percentage of biopsied tissue positive for Gleason pattern 4 (eAPP4) in low dose rate prostate brachytherapy: Evaluation of prognostic utility in a large cohort.
Casey G; Quon H; Meyer T; Sia M; Thind K; Das S; Cho D; McGeachy P; Husain S; Martell K
Radiother Oncol; 2023 Nov; 188():109859. PubMed ID: 37604278
[TBL] [Abstract][Full Text] [Related]
11. Patient age as a predictive factor in biochemical recurrence following brachytherapy: Oncological outcomes at a single center.
Takeuchi S; Iinuma K; Nakano M; Kawase M; Kato D; Kawase K; Takai M; Nakane K; Ito M; Kumano T; Matsuo M; Koie T
Prostate Int; 2022 Dec; 10(4):224-228. PubMed ID: 36570651
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.
Chu W; Loblaw DA; Chan K; Morton G; Choo R; Szumacher E; Danjoux C; Pignol JP; Cheung P
Radiat Oncol; 2015 Apr; 10():95. PubMed ID: 25903934
[TBL] [Abstract][Full Text] [Related]
13. Predictors of distant metastasis after combined HDR brachytherapy and external beam radiation for prostate cancer.
Kamrava M; Rwigema JC; Chung M; Banerjee R; Wang J; Steinberg M; Demanes DJ
J Contemp Brachytherapy; 2013 Sep; 5(3):127-33. PubMed ID: 24143146
[TBL] [Abstract][Full Text] [Related]
14. Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Lief J; Adamovich E; Wallner KE
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e225-32. PubMed ID: 21664066
[TBL] [Abstract][Full Text] [Related]
15. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
16. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy.
Fang LC; Merrick GS; Butler WM; Galbreath RW; Murray BC; Reed JL; Adamovich E; Wallner KE
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):992-6. PubMed ID: 20932674
[TBL] [Abstract][Full Text] [Related]
17. Primary causes of death after permanent prostate brachytherapy.
Bittner N; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Brammer SG; Moyad M
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):433-40. PubMed ID: 18448268
[TBL] [Abstract][Full Text] [Related]
18. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma.
Ragde H; Elgamal AA; Snow PB; Brandt J; Bartolucci AA; Nadir BS; Korb LJ
Cancer; 1998 Sep; 83(5):989-1001. PubMed ID: 9731904
[TBL] [Abstract][Full Text] [Related]
19. Contemporary grading for prostate cancer: implications for patient care.
Brimo F; Montironi R; Egevad L; Erbersdobler A; Lin DW; Nelson JB; Rubin MA; van der Kwast T; Amin M; Epstein JI
Eur Urol; 2013 May; 63(5):892-901. PubMed ID: 23092544
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]